Early drug attack on precancerous blood condition shows promise

This study tested whether starting treatment early for people with high-risk smoldering multiple myeloma—a precancerous blood condition—could delay or prevent it from turning into active cancer. Fifty-five adults received a combination of three drugs (carfilzomib, lenalidomide, and dexamethasone) for eight months, followed by a longer period of maintenance therapy with one drug. The main goal was to see if this aggressive early approach could eliminate all detectable traces of the abnormal cells.